

# Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension

Christian Qvigstad, MD<sup>a,b,\*</sup>, Lars Q. Sørensen, PhD<sup>c</sup>, R. Campbell Tait, MBChB<sup>d</sup>, Philippe de Moerloose, MD<sup>e</sup>, Pål Andre Holme, MD, PhD<sup>a,b</sup>, on behalf of the ADVANCE Working Group

## Abstract

Ageing people with hemophilia (PWH) have a higher prevalence of hypertension than the general population. This study aimed to determine whether macroscopic hematuria was associated with hypertension in PWH in a post hoc analysis using data from a cross-sectional study conducted by the ADVANCE Working Group (the H3 study), which included PWH  $\geq 40$  years of age. Data from 16 contributing centers, located in 13 European countries and Israel, were analyzed using logistic regression models. Of 532 recruited PWH in the H3 study, 117 had hypertension and a positive family history of hypertension (hypertension FH+), 75 had hypertension and a negative family history of hypertension (hypertension FH-), 290 had no diagnosis of hypertension, and the remaining 50 had missing hypertension data. Logistic regressions showed that macroscopic hematuria was associated with hypertension FH+, both in the univariate (OR = 1.84 [1.17–2.90],  $P = .01$ ) and in the multivariate model (OR = 1.80 [1.03–3.16],  $P = .04$ ). Macroscopic hematuria was not associated with hypertension FH-. Moreover, in a multivariate logistic regression the odds of hypertension FH+ were increased with the number of macroscopic hematuria episodes. The association between macroscopic hematuria and hypertension was significant for PWH with a family history of hypertension.

**Abbreviations:** BMI = body mass index, CAD = coronary artery disease, CI = confidence interval, EGFR = estimated glomerular filtration rate, FH- = negative family history of hypertension, FH+ = positive family history of hypertension, HTN = hypertension, IQR = interquartile range, NSAIDs = non-steroidal anti-inflammatory drugs, PWH = people with hemophilia.

**Keywords:** ageing, hematuria, hemophilia, hypertension, logistic regression models

Editor: Alfonso H. Santos.

The ADVANCE Working Group is supported by grant funding from Bayer HealthCare. The sponsor played no role in data collection but was present in meetings and discussions related to the H3 study. CQ reports honoraria and non-financial support from Bayer HealthCare, outside the submitted work. LQS has nothing to disclose. RCT reports honoraria and non-financial support from Bayer HealthCare, CSL Behring, and Novo Nordisk, and honoraria from Pfizer, Sanofi, Shire, and Sobi, outside the submitted work. PdM reports honoraria from Bayer HealthCare, Baxalta, CSL Behring, Novo Nordisk, Shire, and Sobi, outside the submitted work. PAH reports honoraria or research support from Bayer HealthCare, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Shire, and Sobi, outside the submitted work.

The authors report no conflicts of interest.

<sup>a</sup>Department of Haematology Oslo University Hospital, <sup>b</sup>Institute of Clinical Medicine University of Oslo, <sup>c</sup>Independent Researcher, Oslo, Norway, <sup>d</sup>Royal Infirmary, Glasgow, UK, <sup>e</sup>University Hospital and Faculty of Medicine of Geneva, Geneva, Switzerland.

\*Correspondence: Christian Qvigstad, Department of Haematology, Oslo University Hospital Rikshospitalet P. O. Box 4950 Nydalen, Oslo, NO 0424 (e-mail: Qvigstad@gmail.com, Christian.Qvigstad@medisin.uio.no).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Qvigstad C, Sørensen LQ, Tait RC, de Moerloose P, Holme PA. Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension. *Medicine* 2020;99:9 (e19339).

Received: 11 September 2019 / Received in final form: 27 January 2020 / Accepted: 28 January 2020

<http://dx.doi.org/10.1097/MD.00000000000019339>

## 1. Introduction

Hemophilia is an inherited deficiency of clotting factors VIII or IX that is associated with recurrent and spontaneous bleeding, most commonly internal bleedings into joints or muscles.<sup>[1]</sup> Hematuria, the presence of blood in the urine that is either visible (macroscopic) or non-visible (microscopic), is a common condition in people with hemophilia (PWH).<sup>[2,3]</sup>

We have known that adult PWH have a higher incidence of hypertension than the general population since Rosendaal et al<sup>[4]</sup> published their results in 1990. Later studies of cohorts from Europe and North America<sup>[5–8]</sup> have confirmed this finding, but causes for the increased prevalence remain uncertain.<sup>[8]</sup>

Studying renal disease in more than 3000 PWH, Kulkarni et al<sup>[5]</sup> found higher prevalence of hypertension in PWH admitted for kidney bleeds than in those admitted for other reasons. Drygalski et al<sup>[7]</sup> found a positive association between hypertension and risk factors known from the general population, such as age, body mass index (BMI), diabetes, and renal function. Overall, 49.1% of the PWH had hypertension compared with 31.7% in the control group. However, the study lacked data on macroscopic hematuria. Recent research has attempted to establish whether an association between macroscopic hematuria and hypertension exists. Two papers, Holme et al and Sun et al<sup>[9,10]</sup> have concluded that no such associations are discernible in the cohorts analyzed. In sum, the evidence on this topic is mixed.

It is well known that at least two factors increase the likelihood of developing hypertension. First, there exists a genetic component – family history of hypertension significantly

increases the risk of developing hypertension.<sup>[11]</sup> Second, environmental or lifestyle factors, such as obesity, insulin resistance, high alcohol intake, and high salt intake may cause hypertension.<sup>[12]</sup> In addition, prevalence increases with age.

In this paper, we acknowledged that familial and lifestyle risk factors of hypertension need not be identical. In particular, we disentangled familial from non-familial associations by examining whether the association between hematuria and hypertension in PWH was contingent on a family history of hypertension.

## 2. Materials and methods

### 2.1. Data collection

The dataset, consisting of 532 patients aged 40 years and older, was collected between June 2011 and September 2013 by researchers in 16 participating centers, located in 13 European countries and Israel, where Germany had 3 centers and Italy had 2. All data were gathered from consecutive PWH attending their routine clinical visit using a case report form and from laboratory data collected no earlier than 1 year before the clinical visit. The case report form included items about patient characteristics, demographics, past and current treatment, and medical history including a lifetime history of comorbidities. Both a known history of hypertension and a family history of hypertension were recorded as either existent or not. Two consecutive blood pressure measurements were performed as recommended by the European Society of Hypertension,<sup>[13]</sup> and hypertension was defined as either systolic blood pressure above 140 mmHg or diastolic blood pressure above 90 mmHg, or both. Patient-reported hypertension in first-degree relatives was recorded as a positive family history of hypertension (FH+). A history of macroscopic hematuria was recorded as present or absent. Given a positive history of macroscopic hematuria, the number of such episodes was also recorded. Diabetes was considered present if a patient had a known diagnosis or if currently on medication for diabetes. Estimated glomerular filtration rate (EGFR) values were calculated from the measured serum creatinine concentration using the Chronic Kidney Disease Epidemiology Collaboration equation.<sup>[14]</sup> Consenting patients, with any severity of hemophilia A or B, were included in the study. Respective national ethical committees or the institutional review boards approved the study.<sup>[9,15]</sup>

### 2.2. Study design and statistical analyses

In this post hoc analysis, we constructed a categorical hypertension variable that divided the sample into 3 groups:

- (1) No hypertension,
- (2) Hypertension with a positive family history of hypertension (hypertension FH+), and
- (3) Hypertension with a negative family history of hypertension (hypertension FH-).<sup>[11,16]</sup>

Figure 1 details the categorization. To determine associations between hypertension and potential risk factors in PWH, we performed both univariate and multivariate logistic regression analyses for 2 specifications of the dependent variable, that is, 4 regression models in total. First, we created a categorical dependent variable with 3 levels according to the specification above. Second, we collapsed the 2 types of hypertension into one and constructed a binary dependent variable with the levels diagnosis of hypertension vs no hypertension. No hypertension

was set as the baseline for both dependent variables. For the models with a nominal categorical dependent variable, we estimated a multinomial logistic regression (see Level 3 in Fig. 1). For the models comparing no hypertension to a known diagnosis of hypertension, we performed a binomial logistic regression (see Level 4 in Fig. 1).

Differences in baseline characteristics between individuals with and without hypertension and between hypertensive groups FH+ and FH- were assessed using analysis of variance (ANOVA) for continuous variables and the chi-squared test of independence for categorical variables. When these tests implied rejection of the null hypothesis, we performed pairwise comparisons in which we corrected the *P* values for multiple comparisons using Tukey's honestly significant difference test on continuous and the Bonferroni correction on categorical variables.

As shown in Figure 1, 16 observations were lost in the transition from the multinomial (Level 3) to the binomial (Level 4) model due to missing data. The binomial model included family history of hypertension as an independent variable and hence this value was needed for all observations. In contrast, the multinomial model used family history of hypertension only to distinguish between different types of hypertension in the construction of the dependent variable. Consequently, a valid value was not needed for patients without a hypertension diagnosis.

We used R version 3.6.1<sup>[17]</sup> for all analyses, and we considered a two-tailed *P* value less than .05 to be statistically significant.

## 3. Results


### 3.1. Study population

The patients in the study population were 98% Caucasian with median age 52 years (range 40–98). Of the 532 study participants, 87% had hemophilia A and 13% had hemophilia B; 58% had severe, 11% had moderate, and 31% mild hemophilia. A known diagnosis of hypertension was present in 239 individuals, 290 had no hypertension diagnosis, and 3 had missing values for hypertension. Among the 239 hypertensive, a family history of hypertension was present for 117 individuals, no family history for 75, and missing data for the remaining 50 (Levels 1 and 2 in Figure 1).

Table 1 shows descriptive statistics by category of hypertension. Prophylactic therapy was more common among hypertensive FH+ (41%) than among hypertensive FH- (25%). At 67%, the prevalence of macroscopic hematuria was much higher in the hypertensive FH+ group than among other patients, where it was 51%. There was a higher incidence of regular (>3 months per year) non-steroidal anti-inflammatory drugs (NSAIDs) use and diabetes among those classified as hypertensive FH+.

After correcting for multiple comparisons, we found that prevalence of diabetes and history of renal disease was significantly higher for hypertensive than non-hypertensive individuals, while there was no significant difference between hypertensive groups FH+ and FH-. Macroscopic hematuria was significantly more prevalent for hypertensive FH+ than for those with no hypertension. Multiple comparison results for continuous variables showed differences between hypertensive and non-hypertensive and no difference between hypertensive groups FH+ and FH-.

Panels a and b in Figure 2 show occurrence of hypertension and macroscopic hematuria and reveal considerable variation



**Figure 1.** The figure shows the filtering process that leads to the leaf nodes that constitute the levels of the response variables in the two models. FH– = negative family history of hypertension, FH+ = positive family history of hypertension, HTN = hypertension.

between countries. Panel b shows a scatter plot of the fraction of PWH with macroscopic hematuria and hypertension FH+, where each point represents a country. The regression line indicates that prevalence of hypertension FH+ increases with prevalence of hematuria, when considered at the country level.

### 3.2. Regression models

Table 2 shows results from univariate logistic regressions of hypertension on macroscopic hematuria and several other covariates. The reference level is no hypertension for all models. Panel A in the table reveals that macroscopic hematuria was only significantly associated with hypertension FH+. There was no effect from hematuria on hypertension FH–, nor when not distinguishing by type of hypertension. Panel B shows univariate results for control variables included in the multivariate models.

For all categories of hypertension, each control was significantly associated with hypertension except severe hemophilia. Significant covariates not included in the multivariate models are shown in Panel C. The first column in the table shows that the odds of contracting hypertension when FH+ was present were 1.84 (1.17–2.90) times higher for patients with macroscopic hematuria, with a  $P = .01$ . To examine the robustness of this finding, we included clinically relevant controls in multivariate analyses.

The multivariate analyses (Table 3) confirmed that macroscopic hematuria was a significant covariate, but only for hypertension FH+ ( $P = .04$ ). Age and BMI, well-known risk factors for hypertension in the general population, were both highly significant for all categories of hypertension. Additionally, low EGFR and severe hemophilia were associated with hypertension of all classifications. Severe hemophilia only became a significant covariate after adjusting for age and BMI. On

**Table 1**  
Descriptive statistics by type of hypertension.

	Total		Hypertension FH+		Hypertension FH-		No hypertension		P value
	n	(%)	n	(%)	n	(%)	n	(%)	
Type									
Hemophilia A	419	(87)	100	(85)	63	(84)	256	(88)	.54
Hemophilia B	63	(13)	17	(15)	12	(16)	34	(12)	
Severity									
Mild	150	(31)	39	(33)	27	(36)	84	(29)	.55
Moderate	52	(11)	10	(9)	6	(8)	36	(12)	
Severe	279	(58)	68	(58)	42	(56)	169	(58)	
Measures									
Age, mean (IQR)	55	(45–62)	59	(51–68)	62	(52–71)	51	(43–56)	<.001 <sup>*,†</sup>
BMI, mean (IQR)	25.7	(23.2–27.5)	27.4	(24.1–29.4)	26.3	(23.9–27.7)	24.8	(23.0–26.6)	<.001, * .01 <sup>†</sup>
EGFR, mean (IQR)	94	(85–107)	88	(74–103)	84	(69–98)	100	(91–109)	<.001 <sup>*,†</sup>
Treatment									
On demand	294	(61)	67	(57)	53	(71)	174	(60)	.37
No treatment	1	(0)	0	(0)	0	(0)	1	(0)	
Bypass	16	(3)	2	(2)	3	(4)	11	(4)	
Prophylaxis	171	(35)	48	(41)	19	(25)	104	(36)	
Smoker									
No	239	(50)	56	(48)	40	(54)	143	(50)	.32
Yes	112	(23)	24	(21)	13	(18)	75	(26)	
Previously	127	(27)	37	(32)	21	(28)	69	(24)	
Alcohol consumption									
Abstinent	185	(39)	42	(37)	31	(42)	112	(40)	.47
Low	214	(46)	53	(46)	28	(38)	133	(47)	
High	71	(15)	19	(17)	14	(19)	38	(13)	
Comorbidities									
NSAIDs	93	(19)	29	(25)	12	(16)	52	(18)	.20
Diabetes	45	(9)	24	(21)	12	(16)	9	(3)	<.001 <sup>*,†</sup>
History of renal disease	27	(6)	11	(9)	11	(15)	5	(2)	.01, * <.001 <sup>†</sup>
Macroscopic hematuria	264	(55)	78	(67)	38	(51)	148	(51)	.03, * >.99 <sup>†</sup>
<3 bleeds	123	(26)	34	(29)	14	(19)	75	(27)	
3–10 bleeds	75	(16)	22	(19)	14	(19)	39	(14)	
>10 bleeds	67	(14)	22	(19)	10	(14)	35	(12)	

This table shows descriptive statistics by category of hypertension. The numbers in parentheses report percentages per corresponding group, except for the comorbidities group where they are reported per hypertension category. Deviations from the corresponding total are due to rounding. P values are estimated using analysis of variance (ANOVA) for continuous and the chi-squared test of independence for categorical variables. If the P value implies that the null hypothesis is rejected, we report instead pairwise P values using Tukey's honestly significant difference test for continuous and Bonferroni's post hoc test for categorical variables.

BMI = body mass index, EGFR = estimated glomerular filtration rate, FH- = negative family history of hypertension, FH+ = positive family history of hypertension, IQR = interquartile range, NSAIDs = non-steroidal anti-inflammatory drugs.

\* P value obtained by comparing the hypertensive FH+ group with the no hypertension group.


† P value obtained by comparing the hypertensive FH- group with the no hypertension group.

average, individuals with severe hemophilia were younger and had lower BMI than those with non-severe hemophilia among the patients included under the heading “Hypertension FH+” in Tables 1 and 2. Therefore, in order to assess the association between severity of hemophilia and hypertension, we needed to control for these 2 risk factors. Macroscopic hematuria and severity of hemophilia were highly correlated, as evidenced by a chi-squared test strongly rejecting independence ( $P < .001$ ). As is often the case with correlated covariates, removing one will increase the significance of the remaining. Unreported results showed that removing severity of hemophilia from the multivariate regression reduced the P value for macroscopic hematuria to .001. We chose to include severity in the regression, however, to demonstrate that macroscopic hematuria remained a significant association even after controlling for severity. Only for hypertension FH- was diabetes not significant at the 5% level ( $P = .12$ ). As expected, a family history of hypertension was highly significant for undifferentiated hypertension ( $P < .001$ ). We cannot include a family history of hypertension as a covariate

in the multinomial regression, however, since we used this variable in the construction of the dependent variable. We found no evidence of interaction effects among the explanatory variables.

We performed the Cochran–Mantel–Haenszel test to assess the association between hypertension FH+ and macroscopic hematuria, stratified by country. Consistent with the logistic regression results, the test rejected independence with a P value equal to .03.

We further examined whether the effect from macroscopic hematuria on hypertension was binary, or whether more occurrences of macroscopic hematuria increased the likelihood of hypertension FH+. In Table 4, we substituted the dichotomous variable macroscopic hematuria with the number of bleeding episodes and dropped severity of hemophilia due to its strong correlation with the number of bleeding episodes. The odds of hypertension FH+ increased with the number of macroscopic hematuria episodes, from 1.98 (1.05–3.72) for less than 3 bleeding episodes to 3.14 (1.51–6.55) for more than 10 episodes. All 3 levels were significant compared to the baseline, which was



**Figure 2.** The figure shows plots of occurrence of hypertension and macroscopic hematuria by country. Panel a shows the fraction of patients with hypertension FH+, hypertension FH-, and no hypertension per country, sorted by prevalence of hypertension FH+. Panel b shows a scatter plot with macroscopic hematuria on the horizontal axis and hypertension FH+ on the vertical axis. The size of each point reflects the number of recruited patients per country. The slope is a least squares regression line where each country is equally weighted. FH- = negative family history of hypertension, FH+ = positive family history of hypertension.

**Table 2**

**Univariate logistic regressions of hypertension on macroscopic hematuria and covariates.**

Variable	Hypertension FH+			Hypertension FH-			Hypertension (all)		
	Odds Ratio	95% CI	P value	Odds Ratio	95% CI	P value	Odds Ratio	95% CI	P value
Panel A:									
Macroscopic hematuria	1.84	(1.17, 2.90)	.01	0.95	(0.57, 1.58)	.84	1.23	(0.86, 1.75)	.25
Panel B: Controls included in the multivariate models									
Age	1.08	(1.06, 1.11)	<.001	1.10	(1.07, 1.13)	<.001	1.09	(1.07, 1.11)	<.001
BMI	1.18	(1.11, 1.25)	<.001	1.11	(1.04, 1.19)	<.001	1.16	(1.11, 1.23)	<.001
EGFR	0.96	(0.95, 0.97)	<.001	0.95	(0.94, 0.97)	<.001	0.96	(0.95, 0.97)	<.001
Diabetes	8.00	(3.59, 17.83)	<.001	6.00	(2.42, 14.86)	<.001	7.07	(3.53, 15.77)	<.001
Severe hemophilia	0.99	(0.64, 1.52)	.95	0.90	(0.54, 1.51)	.70	1.02	(0.72, 1.45)	.90
Family history of HTN	-	-	-	-	-	-	3.28	(2.24, 4.85)	<.001
Panel C: Significant covariates not included in multivariate models									
History of renal disease	5.85	(1.99, 17.24)	<.001	9.69	(3.25, 28.87)	<.001	6.45	(2.62, 19.39)	<.001
NSAIDs	1.52	(0.91, 2.55)	.11	0.88	(0.44, 1.75)	.71	1.62	(1.06, 2.49)	.02
History of CAD	8.97	(3.20, 25.10)	<.001	6.86	(2.17, 21.65)	<.001	7.49	(3.08, 22.39)	<.001

This table shows univariate logistic regressions for several covariates for hypertensive individuals with FH+ and FH-, and for all hypertensive individuals (ie, not differentiated by a family history of hypertension). The baseline category is no hypertension for all categories of hypertension. Dashes represent a covariate not analyzed in that regression model.

BMI = body mass index, CAD = coronary artery disease, CI = confidence interval, EGFR = estimated glomerular filtration rate, FH- = negative family history of hypertension, FH+ = positive family history of hypertension, HTN = hypertension, NSAIDs = non-steroidal anti-inflammatory drugs.

Downloaded from http://journals.lww.com/med-journal by BNDMf5epHKav1Eoum1QIN4a+kLLhEZgbsHio4XMM0hOcy on 11/14/2024



transplanted with kidneys from donors with hypertension FH+. Moreover, van Hooft et al<sup>[22]</sup> found lower renal blood flow and higher renal vascular resistance in individuals with hypertensive parents than in those with normotensive parents, and that these hemodynamic changes take place at an early stage in the development of hypertension when FH+ was present. When combined with a new stressor such as macroscopic hematuria, this predisposition can be accelerated and result in hypertension. In our view, the impact of hematuria on renal function is a possible cause of hypertension when FH+ is present.

Several variables were significant in univariate regressions (Table 2), but became non-significant after the inclusion of additional controls. For example, the regular use of NSAIDs, known to induce various sorts of kidney damage,<sup>[23]</sup> was associated with hypertension in univariate analysis for undifferentiated hypertension only. Regular NSAIDs use and severe hemophilia were highly correlated, as the use of NSAIDs was more common among people with severe than mild hemophilia. After controlling for age, BMI, and severity of hemophilia, use of NSAIDs became non-significant in multivariate analysis. A history of renal disease was also a significant covariate in univariate analysis, but very few patients had this diagnosis (Table 1) whereas EGFR was available for nearly the entire cohort. Renal disease became non-significant after controlling for EGFR. We found a positive association between hypertension and a history of coronary artery disease (CAD) both in univariate and multivariate regressions. However, this was most likely a consequence of reverse causation, as hypertension is a well-known risk factor for the structural and vascular changes that develop in CAD.<sup>[24,25]</sup> Hence, this variable was not included in the final model.

It has generally been thought that macroscopic hematuria is a benign condition in PWH. However, this paper demonstrated its association with hypertension FH+. This result is clinically important as hypertension in turn can lead to further renal damage, cardiac disease, peripheral vascular disease, and stroke. An increased attention given to macroscopic hematuria may restrict these adverse outcomes. In a recent study,<sup>[26]</sup> we documented that frequent prophylaxis is negatively associated with macroscopic hematuria. The results in this paper indicate that frequent prophylaxis and treatment of hematuria may reduce the likelihood of developing hypertension FH+. Although a family history of hypertension by itself is an immutable risk factor, awareness of the possible development of hypertension FH+ is important for appropriate prevention and intervention. Monitoring blood pressure at regular visits will identify the patients with hematuria at risk for hypertension and progression to renal damage.

## 5. Limitations

This study has some limitations. As the study is from cross-sectional data, it is statistically difficult to differentiate between causes and consequences of hypertension, although theory and previous studies guide our hypotheses regarding causality. Additional limitations were that most data were collected retrospectively, possibly susceptible to misclassification due to recall bias, and that missing data caused the removal of some patients in the regression analyses. Also, inherited causes of hematuria such as certain familial kidney diseases could potentially explain the correlation between hematuria and hypertension. Unfortunately, this information was not available

in our study. These limitations notwithstanding, the paper adds new insight to hypertension in PWH. The H3 study<sup>[9]</sup> represents a comprehensive multi-country hemophilia sample that adds to the generalizability of the strong association between macroscopic hematuria and hypertension FH+.

## 6. Conclusion

In this paper, we demonstrated the need to differentiate hypertension FH+ from FH- in order to recognize that macroscopic hematuria is in fact associated with hypertension. To our knowledge, this distinction has not been applied in the previous literature. We acknowledge that the results pertain to this study sample only, and encourage more research to establish out of sample evidence to ascertain whether the association between hypertension FH+ and hematuria holds more generally.

## Acknowledgments

The authors wish to thank the centers that contributed data: Austria (Vienna Adult Hemophilia Center), Germany (Vivantes Klinikum im Friedrichshain, Berlin, University Clinic Bonn, Kurpfalz Hospital and Haemophilia Centre, Heidelberg), Greece (Hippokratia Hospital, Athens), Israel (Sheba Medical Center, Tel Hashomer, Chaim Sheba Medical Center, Tel Aviv), Italy (IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, University Hospital of Parma), The Netherlands (University Medical Center Utrecht), Norway (Oslo University Hospital), Poland (Institute of Haematology and Blood Transfusion, Warsaw) Slovenia (University Medical Centre, Ljubljana), Spain (Virgen del Rocío Hospital, Seville), Sweden (Lund University, Malmö), Switzerland (University Hospital of Geneva), United Kingdom (Royal Infirmary, Glasgow).

## Author contributions

CQ designed the research study, performed the research, analyzed the data, and wrote the paper. LQS designed the research study and participated in the research, data analysis, and in writing the manuscript. RCT, PdM, and PAH designed the research study and participated in writing the manuscript. Christian Qvigstad orcid: 0000-0003-1419-6465.

## References

- [1] Srivastava A, Brewer A, Mauser-Bunschoten E, et al. Guidelines for the management of hemophilia. *Haemophilia* 2013;19:e1-e47.
- [2] Prentice C, Lindsay R, Barr R, et al. Renal complications in haemophilia and Christmas disease. *QJM* 1971;40:47-61.
- [3] Beck P, Evans K. Renal abnormalities in patients with haemophilia and Christmas disease. *Clin Radiol* 1972;23:349-54.
- [4] Rosendaal F, Briet E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. *Br J Haematol* 1990;75:525-30.
- [5] Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. *Haemophilia* 2003;9:703-10.
- [6] van de Putte DEF, Fischer K, Makris M, et al. Increased prevalence of hypertension in haemophilia patients. *Thromb Haemost* 2012;108:750-5.
- [7] von Drygalski A, Kolaitis NA, Bettencourt R, et al. Prevalence and risk factors for hypertension in hemophilia. *Hypertension* 2013;62:209-15.
- [8] Barnes RF, Cramer TJ, Sait AS, et al. The hypertension of hemophilia is not explained by the usual cardiovascular risk factors: results of a cohort study. *Int J Hypertens* 2016;2016:1-3. doi:10.1155/2016/2014201 Article ID 2014201.

- [9] Holme PA, Combescure C, Tait RC, et al. Hypertension, haematuria and renal functioning in haemophilia – a cross-sectional study in Europe. *Haemophilia* 2016;22:248–55.
- [10] Sun H, Yang M, Sait A, et al. Haematuria is not a risk factor of hypertension or renal impairment in patients with haemophilia. *Haemophilia* 2016;22:549–55.
- [11] Wang N-Y, Young JH, Meoni LA, et al. Blood pressure change and risk of hypertension associated with parental hypertension: the Johns Hopkins Precursors Study. *Arch Intern Med* 2008;168:643–8.
- [12] Carretero OA, Oparil S. Essential hypertension: part I: definition and etiology. *Circulation* 2000;101:329–35.
- [13] Mancia G, Fagard R, Narkiewicz K, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens* 2013;31:1925–38.
- [14] Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–12.
- [15] Qvigstad C, Tait RC, Rauchensteiner S, et al. The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. *Medicine* 2018;97:e12551.
- [16] Winnicki M, Somers VK, Dorigatti F, et al. Lifestyle, family history and progression of hypertension. *J Hypertens* 2006;24:1479–87.
- [17] R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. Available at: <https://www.R-project.org/>. Accessed August 1, 2019
- [18] Garrison RJ, Kannel WB, Stokes JIII, et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. *Prev Med* 1987;16:235–51.
- [19] Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney Int* 1999;56:2214–9.
- [20] Simonson DC. Etiology and prevalence of hypertension in diabetic patients. *Diabetes Care* 1988;11:821–7.
- [21] Guidi E, Menghetti D, Milani S, et al. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. *J Am Soc Nephrol* 1996;7:1131–8.
- [22] van Hoof IM, Grobbee DE, Derkx FH, et al. Renal hemodynamics and the renin–angiotensin–aldosterone system in normotensive subjects with hypertensive and normotensive parents. *N Engl J Med* 1991;324:1305–11.
- [23] Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. *Am J Med* 2007;120:280–1.
- [24] Kulkarni R, Soucie JM, Evatt BL. Prevalence and risk factors for heart disease among males with hemophilia. *Am J Hematol* 2005;79:36–42.
- [25] Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. *Blood Coagul Fibrinolysis* 2011;22:402–6.
- [26] Qvigstad C, Tait RC, de Moerloose P, et al. on behalf of the ADVANCE Working Group. Hematuria in aging men with hemophilia: association with factor prophylaxis. *Res Pract Thromb Haemost* 2020;00:1–9.